Virax Biolabs Group Ltd (VRAX) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
VRAX currently has 7.42M outstanding shares. with significant dilution risk as 851M authorized shares could dilute existing holders by 11470.1%. The company has significantly diluted shareholders by 139.66% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Dec 18, 2025 |
F-3 filing: F-3 filing for ordinary shares offered by Selling Stockholders pursuant to a prospectus. |
7.4M | 850M |
| Jul 02, 2025 |
20-F filing | 4.3M shares outstanding |
4.3M | 830M |
| Aug 20, 2024 |
20-F filing | 2.6M shares outstanding |
2.6M | 830M |
| Dec 05, 2023 |
F-3 filing: The filing is for a shelf offering of up to US$30,000,000 of any combination of Ordinary Shares, Preferred Shares, and Debt Securities. |
15M | 820M |
| Jun 14, 2023 |
20-F filing | 15.5M shares outstanding |
16M | 820M |
| Mar 22, 2023 |
F-1 filing: This F-1 filing registers the resale of up to 11,453,062 ordinary shares by selling shareholders, including PIPE Shares, Pre-Funded Warrant Shares, shares issuable upon exercise of Series A and B Options, and shares issuable upon exercise of placement agent warrants. |
820M | 17M |
| Nov 21, 2022 |
F-1 filing: This F-1 filing registers the resale of up to 5,825,000 ordinary shares by selling shareholders, consisting of PIPE Shares, Pre-Funded Warrant Shares, and Warrant Shares. |
820M | 5.8M |
| Aug 12, 2022 |
20-F filing | 815.7M shares outstanding |
820M | 0 |